It was a pleasure to meet with Prof. Mahmoud Ghannoum (Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, USA) to discuss a phase 3 study investigating oteseconazole in the treatment of recurrent vulvovaginal candidiasis.
The abstract entitled: ‘Susceptibility Testing of Oteseconazole (VT-1161) Against Clinical Isolates from Phase 3 Clinical Studies in Subjects with Recurrent Vulvovaginal Candidiasis‘ was presented at IDWeek 2021 (Virtual), 28 September – 3 October 2021.
Questions:
- What is the mechanism of action of oteseconazole? (0:05)
- What are the aims, and design of the phase 3 oteseconazole study? (1:05)
- What were the efficacy and safety findings of this study? (3:13)
- What questions remain unanswered about the use of oteseconazole in VVC and what future studies are planned? (5:26)
Disclosures: Mahmoud Ghannoum is contracted to conduct research from Mycovia pharmaceuticals, Scynexis, Amplyx Pharma, Gilead and Pfizer.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of IDWeek, Virtual 2021
